Also trades as: NAMSW (NASDAQ) · $vol 0M
NAMS NASDAQ
NewAmsterdam Pharma Company N.V.
1W: -4.6%
1M: -13.5%
3M: -30.2%
YTD: -44.5%
1Y: -46.2%
3Y: +160.4%
5Y: +99.5%
$20.43
+0.90 (+4.58%)
Weekly Expected Move ±7.7%
$17
$18
$20
$21
$23
Credit Risk of going bust: lower than 96% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), NewAmsterdam Pharma Company N.V. would be worth roughly what it owes.
Total debt $82K against a stock market value of $2.28B.
Distance to default 20.42 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41K (short-term plus half of long-term), stock volatility 53.0%; Altman Z'' 8.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $82K against a stock market value of $2.28B.
Distance to default 20.42 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41K (short-term plus half of long-term), stock volatility 53.0%; Altman Z'' 8.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.3B
52W Range19.13-42.21
Volume1,564,037
Avg Volume1,331,764
Beta0.10
Dividend—
Analyst Ratings
Company Info
CEOMichael Harvey Davidson Facp.
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden, NH 1411 DC
NL
Naarden, NH 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerâs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Biggest stock movers Tuesday: ZIM, NVS, and more
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kastelein Johannes J | M-Exempt | 50,246 | — | 2026-09-30 |
| Kastelein Johannes J | S-Sale | 50,246 | $25.03 | 2026-09-30 |
| Kastelein Johannes J | M-Exempt | 50,246 | — | 2026-09-30 |
| Davidson Michael H. | P-Purchase | 10,000 | $22.65 | 2026-09-14 |
| Smither John W | S-Sale | 1,600 | $25.32 | 2026-09-04 |